<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="243">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936438</url>
  </required_header>
  <id_info>
    <org_study_id>INTERCATH</org_study_id>
    <nct_id>NCT04936438</nct_id>
  </id_info>
  <brief_title>Clinical Cohort Study - INTERCATH</brief_title>
  <official_title>Clinical Cohort Study - INTERCATH: A Diseased Cohort Based Epidemiologic, Prospective, Single Center Cohort Study for Novel Research in Cardiovascular Risk Prediction Using a Sophisticated Biobank</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Within a CAD patient cohort there is a wide variability of clinical manifestation and&#xD;
      severity of coronary disease. Distinct determinants that would explain the variety of CAD&#xD;
      phenotypes with differing prognosis are yet undiscovered. Aim of this study is to find&#xD;
      genetic variants, biomarkers, and clinical cardiovascular risk factors that relate to&#xD;
      specific coronary artery disease phenotypes and related pathologies in a patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherosclerotic Coronary Artery Disease (CAD) is one of the leading causes of death in&#xD;
      industrialized countries and accounts for a high lifetime prevalence. Within a CAD patient&#xD;
      cohort there is a broad inter-individual difference with regard to clinical manifestation and&#xD;
      severity of disease, e.g. stable angina vs. acute coronary syndrome, calcified vs. thrombotic&#xD;
      coronary lesions or one vessel vs. complex three vessel disease or left main stenosis. Thus,&#xD;
      depending on the CAD phenotype there is a broad difference in CAD patients' prognosis.&#xD;
      Similarly, other non-atherosclerotic coronary pathologies such as Spontaneous Coronary&#xD;
      Dissection (SCAD) are related with devastating illness in mainly young patients. For these&#xD;
      patients there is an unmet need in the knowledge of epidemiology, presentation, current&#xD;
      management and outcome. Aim of this study is to discover genetic variants, biomarkers, and&#xD;
      clinical cardiovascular risk factors that relate to specific CAD (and related coronary&#xD;
      pathologies) phenotypes in a national patient population. This may allow an improvement of&#xD;
      individualized risk stratification and contribute to discover pathways in the pathogenesis&#xD;
      and open the avenue for potential therapeutic targets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Number of patients with non-fatal or fatal major adverse cardiovascular events (MACE)</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>MACE as a composite endpoint consists of&#xD;
occurrence of non-fatal and fatal myocardial infarction&#xD;
occurrence of non-fatal and fatal stroke&#xD;
need for coronary revascularization (percutaneous coronary intervention or coronary bypass graft operation)&#xD;
Endpoints will be recorded by telephone interview during census follow up. All endpoint information will be validated by official medical records.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Information from the population register will be used to assess all-cause mortality.</description>
  </primary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Syndrome</condition>
  <condition>SCAD</condition>
  <condition>Cardiovascular Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient undergoing coronary angiography.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with a minimum age of 18 years&#xD;
&#xD;
          -  Any patient with an available complete coronary angiography&#xD;
&#xD;
          -  Ability to provide written informed consent in accordance with Good Epidemiological&#xD;
             Practice and local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Physical or psychological incapability to take part in the study&#xD;
&#xD;
          -  Known anaemia (Hemoglobin &lt; 7.5 g/dl)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabian J Brunner, MD</last_name>
    <email>fa.brunner@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Waldeyer, MD</last_name>
    <email>c.waldeyer@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Heart and Vascular Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabian J Brunner, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Christoph Waldeyer, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Blaum C, Seiffert M, Goßling A, Kröger F, Bay B, Lorenz T, Braetz J, Graef A, Zeller T, Schnabel R, Clemmensen P, Westermann D, Blankenberg S, Brunner FJ, Waldeyer C. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort. Eur J Prev Cardiol. 2021 Mar 23;28(1):47-56. doi: 10.1093/eurjpc/zwaa088.</citation>
    <PMID>33580772</PMID>
  </results_reference>
  <results_reference>
    <citation>Brunner FJ, Kröger F, Blaum C, Goßling A, Lorenz T, van Erckelens E, Brätz J, Westermann D, Blankenberg S, Zeller T, Waldeyer C, Seiffert M. Association of high-sensitivity troponin T and I with the severity of stable coronary artery disease in patients with chronic kidney disease. Atherosclerosis. 2020 Nov;313:81-87. doi: 10.1016/j.atherosclerosis.2020.09.024. Epub 2020 Sep 28.</citation>
    <PMID>33032237</PMID>
  </results_reference>
  <results_reference>
    <citation>Blaum C, Brunner FJ, Kröger F, Braetz J, Lorenz T, Goßling A, Ojeda F, Koester L, Karakas M, Zeller T, Westermann D, Schnabel R, Blankenberg S, Seiffert M, Waldeyer C. Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: Implications for an anti-inflammatory treatment target population. Eur J Prev Cardiol. 2021 Apr 10;28(2):152-158. doi: 10.1177/2047487319885458. Epub 2019 Nov 10.</citation>
    <PMID>33838040</PMID>
  </results_reference>
  <results_reference>
    <citation>Waldeyer C, Brunner FJ, Braetz J, Ruebsamen N, Zyriax BC, Blaum C, Kroeger F, Kohsiack R, Schrage B, Sinning C, Becher PM, Karakas M, Zeller T, Westermann D, Sydow K, Blankenberg S, Seiffert M, Schnabel RB. Adherence to Mediterranean diet, high-sensitive C-reactive protein, and severity of coronary artery disease: Contemporary data from the INTERCATH cohort. Atherosclerosis. 2018 Aug;275:256-261. doi: 10.1016/j.atherosclerosis.2018.06.877. Epub 2018 Jun 22.</citation>
    <PMID>29980052</PMID>
  </results_reference>
  <results_reference>
    <citation>Waldeyer C, Seiffert M, Staebe N, Braetz J, Kohsiack R, Ojeda F, Schofer N, Karakas M, Zeller T, Sinning C, Schrage B, Westermann D, Sydow K, Blankenberg S, Brunner FJ, Schnabel RB. Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. Clin Ther. 2017 Nov;39(11):2311-2320.e2. doi: 10.1016/j.clinthera.2017.10.005. Epub 2017 Nov 2.</citation>
    <PMID>29103665</PMID>
  </results_reference>
  <results_reference>
    <citation>Zeller T, Seiffert M, Müller C, Scholz M, Schäffer A, Ojeda F, Drexel H, Mündlein A, Kleber ME, März W, Sinning C, Brunner FJ, Waldeyer C, Keller T, Saely CH, Sydow K, Thiery J, Teupser D, Blankenberg S, Schnabel R. Genome-Wide Association Analysis for Severity of Coronary Artery Disease Using the Gensini Scoring System. Front Cardiovasc Med. 2017 Sep 20;4:57. doi: 10.3389/fcvm.2017.00057. eCollection 2017.</citation>
    <PMID>28979897</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 12, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Fabian J Brunner, MD</investigator_full_name>
    <investigator_title>Co-principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

